Glucagon-Like Peptide-1

DRUG5 trials

Sponsors

Hvidovre University Hospital, Johns Hopkins University, University Hospital, Gentofte, Copenhagen, University of Maryland, Baltimore, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders

Conditions

Critically IllDiabetes Mellitus Type 2HypoglycemiaMaturity-Onset Diabetes of the Young, Type 3Type1 Diabetes MellitusType2diabetes

Early Phase 1

Glucagon-like Peptide-1 in Type 1 Diabetes

WithdrawnNCT04355832

University of Maryland, BaltimoreType1 Diabetes Mellitus

Start: 2020-06-24End: 2025-09-24Updated: 2025-11-07

Phase 2

The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients

TerminatedNCT00798590

Johns Hopkins UniversityCritically Ill, Hypoglycemia

Start: 2008-12-31End: 2011-06-30Updated: 2017-07-02

Phase 4

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Not yet recruitingNCT06449235

Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic DisordersType2diabetes

Start: 2024-09-30End: 2025-06-30Target: 938Updated: 2024-07-16

Unknown Phase

Near Normalisation of BG Improves the Potentiating Effect of GLP-1

CompletedNCT00612625

Hvidovre University HospitalDiabetes Mellitus Type 2

Start: 2004-02-29End: 2004-12-31Updated: 2008-02-12

The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea

CompletedNCT03081676

University Hospital, Gentofte, CopenhagenMaturity-Onset Diabetes of the Young, Type 3

Start: 2017-03-08End: 2018-06-01Updated: 2019-06-27